Epithelial transport of Noscapine across cell monolayer and influence of absorption enhancers on in vitro permeation and bioavailability: implications for intestinal absorption

References

• Segal MS, Goldstein MM, Attinger EO. The use of noscapine (narcotine) as an antitussive agent. Dis Chest 1957;30:305–9
   Google Scholar
• Aneja R, Vangapandu SN, Lopus M, et al. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol 2006;69:1801–9
   PubMed Web of Science ®Google Scholar
• Aneja R, Zhou J, Zhou B, et al. Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice. Mol Cancer Ther 2006;5:2366–77
   PubMed Web of Science ®Google Scholar
• Barken I, Geller J, Rogosnitzky M. Prophylactic noscapine therapy inhibits human prostate cancer progression and metastasis in a mouse model. Anticancer Res 2010;30:399–401
   PubMed Web of Science ®Google Scholar
• Jhaveri N, Cho H, Torres S, et al. Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Lett 2011;312:245–52
   PubMed Web of Science ®Google Scholar
• Li S, He J, Cao G, et al. Noscapine induced apoptosis via downregulation of survivin in human neuroblastoma cells having wild type or null p53. PLoS One 2012;7:e40076
   PubMed Web of Science ®Google Scholar
• Liu M, Luo XJ, Liao F, et al. Noscapine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo. Cancer Chemother Pharmacol 2011;67:605–12
   PubMed Web of Science ®Google Scholar
• Naik PK, Santoshi S, Joshi HC. Noscapinoids with anti-cancer activity against human acute lymphoblastic leukemia cells (CEM): a three dimensional chemical space pharmacophore modeling and electronic feature analysis. J Mol Model 2012;18:307–18
   PubMed Web of Science ®Google Scholar
• Su W, Huang L, Ao Q, et al. Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1alpha. Cancer Lett 2011;305:94–9
   PubMed Web of Science ®Google Scholar
• Yang ZR, Liu M, Peng XL, et al. Noscapine induces mitochondria-mediated apoptosis in human colon cancer cells in vivo and in vitro. Biochem Biophys Res Commun 2012;421:627–33
   PubMed Web of Science ®Google Scholar
• Chougule M, Patel AR, Sachdeva P, et al. Anticancer activity of Noscapine, an opioid alkaloid in combination with cisplatin in human non-small cell lung cancer. Lung Cancer 2011;71:271–82
   PubMed Web of Science ®Google Scholar
• Chougule MB, Patel A, Sachdeva P, et al. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer. PLoS One 2011;6:e27394
   PubMed Web of Science ®Google Scholar
• Chougule MB, Patel AR, Jackson T, Singh M. Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer. PLoS One 2011;6:e17733
   PubMed Web of Science ®Google Scholar
• Jackson T, Chougule MB, Ichite N, et al. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol 2008;63:117–26
   PubMed Web of Science ®Google Scholar
• Aneja R, Zhou J, Vangapandu SN. Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood 2006;107:2486–92
   PubMed Web of Science ®Google Scholar
• Anderson JT, Ting AE, Boozer S, et al. Identification of novel and improved antimitotic agents derived from noscapine. J Med Chem 2005;48:7096–8
   PubMed Web of Science ®Google Scholar
• Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002;2:1–17
   PubMedGoogle Scholar
• Markman M. Managing taxane toxicities. Support Care Cancer 2003;11:144–7
   PubMed Web of Science ®Google Scholar
• Van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001;19:125–41
   PubMed Web of Science ®Google Scholar
• Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev 2011;31:443–81
   PubMed Web of Science ®Google Scholar
• Debono AJ, Xie JH, Ventura S, et al. Synthesis and biological evaluation of N-substituted noscapine analogues. Chem Med Chem 2012;7:2122–33
   Web of Science ®Google Scholar
• Madan J, Baruah B, Nagaraju M, et al. Molecular cycloencapsulation augments solubility and improves therapeutic index of brominated noscapine in prostate cancer cells. Mol Pharm 2012;9:1470–80
   PubMed Web of Science ®Google Scholar
• Naik PK, Chatterji BP, Vangapandu SN, et al. Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid. J Comput Aided Mol Des 2011;25:443–54
   PubMed Web of Science ®Google Scholar
• Naik PK, Lopus M, Aneja R, et al. In silico inspired design and synthesis of a novel tubulin-binding anti-cancer drug: folate conjugated noscapine (Targetin). J Comput Aided Mol Des 2012;26:233–47
   PubMed Web of Science ®Google Scholar
• Mishra RC, Karna P, Gundala SR, et al. Second generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluation. Biochem Pharmacol 2011;82:110–21
   PubMed Web of Science ®Google Scholar
• Madan J, Pandey RS, Jain UK, et al. Sterically stabilized gelatin microassemblies of noscapine enhance cytotoxicity, apoptosis and drug delivery in lung cancer cells. Colloids Surf B Biointerfaces 2013;107:235–44
   PubMed Web of Science ®Google Scholar
• Madan J, Pandey RS, Jain V, et al. Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanomedicine 2013;9:492–503
   PubMed Web of Science ®Google Scholar
• Madan J, Dhiman N, Sardana S, et al. Long-circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. Anticancer Drugs 2011;22:543–55
   PubMed Web of Science ®Google Scholar
• Chandra R, Madan J, Singh P, et al. Implications of nanoscale based drug delivery systems in delivery and targeting tubulin binding agent, noscapine in cancer cells. Curr Drug Metab 2012;13:1476–83
   PubMed Web of Science ®Google Scholar
• Sebak S, Mirzaei M, Malhotra M, et al. Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanomed 2010;5:525–32
   PubMed Web of Science ®Google Scholar
• Karlsson MO, Dahlstrom B, Eckernas SA, et al. Pharmacokinetics of oral noscapine. Eur J Clin Pharmacol 1990;39:275–9
   PubMed Web of Science ®Google Scholar
• Lemmer HJ, Hamman JH. Paracellular drug absorption enhancement through tight junction modulation. Expert Opin Drug Deliv 2013;10:103–14
   PubMed Web of Science ®Google Scholar
• Sonaje K, Chuang EY, Lin KJ, et al. Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. Mol Pharm 2012;9:1271–9
   PubMed Web of Science ®Google Scholar
• Maestrelli F, Cirri M, Mennini N, et al. Improvement of oxaprozin solubility and permeability by the combined use of cyclodextrin, chitosan, and bile components. Eur J Pharm Biopharm 2011;78:385–93
   PubMed Web of Science ®Google Scholar
• Shah P, Jogani V, Mishra P, et al. Modulation of ganciclovir intestinal absorption in presence of absorption enhancers. J Pharm Sci 2007;96:2710–22
   PubMed Web of Science ®Google Scholar
• Mahmoudian M, Rahimi-Moghaddam P. The anti-cancer activity of noscapine: a review. Recent Pat Anticancer Drug Discov 2009;4:92–7
   PubMed Web of Science ®Google Scholar
• Patel AR, Spencer SD, Chougule MB, et al. Pharmacokinetic evaluation and in vitro–in vivo correlation (IVIVC) of novel methylene-substituted 3,3′-diindolylmethane (DIM). Eur J Pharm Sci 2012;46:8–16
   PubMed Web of Science ®Google Scholar
• Aneja R, Dhiman N, Idnani J, et al. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol 2007;60:831–9
   PubMed Web of Science ®Google Scholar
• Madan J, Dhiman N, Parmar VK, et al. Inclusion complexes of noscapine in beta-cyclodextrin offer better solubility and improved pharmacokinetics. Cancer Chemother Pharmacol 2010;65:537–48
   PubMed Web of Science ®Google Scholar
• Abdalla MO, Karna P, Sajja HK, et al. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J Control Release 2011;149:314–22
   PubMed Web of Science ®Google Scholar
• Zhou R, Moench P, Heran C, et al. pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model. Pharm Res 2005;22:188–92
   PubMed Web of Science ®Google Scholar
• Tomita M, Doi N, Hayashi M. Effects of acylcarnitines on efflux transporting system in Caco-2 cell monolayers. Eur J Drug Metab Pharmacokinet 2010;35:1–7
   PubMed Web of Science ®Google Scholar
• Duvvuri M, Krise JP. A novel assay reveals that weakly basic model compounds concentrate in lysosomes to an extent greater than pH-partitioning theory would predict. Mol Pharm 2005;2:440–8
   PubMed Web of Science ®Google Scholar
• Yeh TH, Hsu LW, Tseng MT, et al. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 2011;32:6164–73
   PubMed Web of Science ®Google Scholar
• Schipper NG, Varum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm Res 1996;13:1686–92
   PubMed Web of Science ®Google Scholar
• Kale R, Tayade P, Saraf M, Juvekar A. Molecular encapsulation of thalidomide with sulfobutyl ether-7 beta-cyclodextrin for immediate release property: enhanced in vivo antitumor and antiangiogenesis efficacy in mice. Drug Dev Ind Pharm 2008;34:149–56
   PubMed Web of Science ®Google Scholar
• Holvoet C, Heyden YV, Plaizi-Vercammen J. Inclusion complexation of diazepam with different cyclodextrins in formulations for parenteral use. Pharmazie 2005;60:598–603
   PubMed Web of Science ®Google Scholar
• Kurkov SV, Madden DE, Carr D, Loftsson T. The effect of parenterally administered cyclodextrins on the pharmacokinetics of coadministered drugs. J Pharm Sci 2012;101:4402–8
   PubMed Web of Science ®Google Scholar
• Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009;6:659–68
   PubMed Web of Science ®Google Scholar
• Saremi S, Dinarvand R, Kebriaeezadeh A, et al. Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: preparation, in vitro and in vivo studies. Biomed Res Int 2013;2013:150478 (1–8)
   Web of Science ®Google Scholar
• Anderberg EK, Artursson P. Epithelial transport of drugs in cell culture. VIII: effects of sodium dodecyl sulfate on cell membrane and tight junction permeability in human intestinal epithelial (Caco-2) cells. J Pharm Sci 1993;82:392–8
   PubMed Web of Science ®Google Scholar
• Gupta V, Hwang BH, Doshi N, Mitragotri S. A permeation enhancer for increasing transport of therapeutic macromolecules across the intestine. J Control Release 2013;172:541–9
   PubMed Web of Science ®Google Scholar
• Thanou M, Henderson S, Kydonieus A, Elson C. N-Sulfonato-N,O-carboxymethylchitosan: a novel polymeric absorption enhancer for the oral delivery of macromolecules. J Control Release 2007;117:171–8
   PubMed Web of Science ®Google Scholar
• Wu J, Shen Q, Fang L. Sulfobutylether-beta-cyclodextrin/chitosan nanoparticles enhance the oral permeability and bioavailability of docetaxel. Drug Dev Ind Pharm 2013;39:1010–19
   PubMed Web of Science ®Google Scholar
• Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994;11:1358–61
   PubMed Web of Science ®Google Scholar
• Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev 2001;52:117–26
   PubMed Web of Science ®Google Scholar
• Chen MC, Mi FL, Liao ZX, et al. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv Drug Deliv Rev 2013;65:865–79
   PubMed Web of Science ®Google Scholar
• Martins PS, Ochoa R, Pimenta AM, et al. Mode of action of beta-cyclodextrin as an absorption enhancer of the water-soluble drug meglumine antimoniate. Int J Pharm 2006;325:39–47
   PubMed Web of Science ®Google Scholar
• Cano-Cebrian MJ, Zornoza T, Granero L, Polache A. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr Drug Deliv 2005;2:9–22
   PubMedGoogle Scholar
• Joshi HC, Zhou J. Noscapine and analogues as potential chemotherapeutic agents. Drug News Perspect 2000;13:543–6
   PubMed Web of Science ®Google Scholar
• Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 2012;64:557–70
   PubMed Web of Science ®Google Scholar